IPSC (Century Therapeutics) Buyback Yield %: -30.33 (As of Jul. 08, 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.32
GF Value $38.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Buyback Yield %?

Century Therapeutics IPSC -3.75% 46 Buyback Yield % is -30.33 as of Jul. 08, 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 741 Biotechnology companies, Century Therapeutics ranks worse than 76.65% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Century Therapeutics's current buyback yield was -30.33%.


Century Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Buyback Yield % Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -25.40 -9.05 -0.26 -86.01 -0.20

Century Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.76 0.43 1.12 -0.20 -31.11

IPSC vs PBYI, BNTC, ENTA: Buyback Yield % Comparison

For the Biotechnology subindustry, Century Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Buyback Yield % falls into.


IPSC
46GF Score
Century Therapeutics Inc IPSC
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Century Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.173) / 87.0639012
=-0.20%

Century Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 126.623) / 407.03052
=-31.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -30.33 mean?
Century Therapeutics (IPSC) has a Buyback Yield % of -30.33 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Century Therapeutics and its competitors. According to the industry distribution chart, Century Therapeutics ranks #568 out of 741 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Century Therapeutics' Buyback Yield % too high?
Century Therapeutics' current Buyback Yield % is -30.33. Based on the distribution chart, Century Therapeutics ranks #568 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Buyback Yield % compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #568 out of 741 companies for Buyback Yield %. This places Century Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current Buyback Yield % is -30.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current Buyback Yield % is -30.33. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Buyback Yield % is -30.33 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Buyback Yield %: -30.33
  • GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.32
Price
$38.91
GF Value